Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/IB2015/050650, filed Jan 28, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,087,245 | Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof F. Hoffmann-La Roche AG, Institut Pasteur, Commissariat a l'Energie Atomique et aux Energies Alternatives and Centre National de la Recherche Scientifique (CNRS) In force · High confidence | F. Hoffmann-La Roche AG, Institut Pasteur, Commissariat a l'Energie Atomique et aux Energies Alternatives and Centre National de la Recherche Scientifique (CNRS) | In force | High confidence | ||
| US 10,538,582 | Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof In force · High confidence | Centre National de la Recherche Scientifique (CNRS) | In force | High confidence | ||
| US 11,124,563 | Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof In force · Medium confidence | Centre National de la Recherche Scientifique (CNRS) | In force | Medium confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.